Tadafumi Hashimoto

List of Publications by Year
in descending order

55 papers	4,929 citations	109264 35 h-index	155592 55 g-index
61 all docs	61 docs citations	61 times ranked	7321 citing authors

#	Article	IF	Citations
1	Oligomeric amyloid Î² associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4012-4017.	3.3	734
2	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. American Journal of Pathology, 2012, 181, 1426-1435.	1.9	369
3	Amyloid Î² Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. Journal of Neuroscience, 2010, 30, 2636-2649.	1.7	328
4	Heatâ€shock protein 70 modulates toxic extracellular Î±â€synuclein oligomers and rescues transâ€synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.2	276
5	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	3.7	268
6	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	1.7	219
7	Chronic Optogenetic Activation Augments AÎ² Pathology in a Mouse Model of Alzheimer Disease. Cell Reports, 2015, 11, 859-865.	2.9	186
8	CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO Journal, 2002, 21, 1524-1534.	3.5	184
9	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-? concentrations. Annals of Neurology, 2000, 48, 806-808.	2.8	135
10	Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 2013, 5, 212ra161.	5.8	135
11	Soluble oligomeric amyloid-Î² induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Molecular Neurodegeneration, 2017, 12, 27.	4.4	120
12	Brain Oligomeric Î²-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2011, 70, 360-376.	0.9	111
13	AÎ² Immunotherapy: Intracerebral Sequestration of AÎ² by an Anti-AÎ² Monoclonal Antibody 266 with High Affinity to Soluble AÎ². Journal of Neuroscience, 2009, 29, 11393-11398.	1.7	103
14	Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid Î²-Peptide by the Liver. Pharmaceutical Research, 2006, 23, 1407-1416.	1.7	100
15	The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid Î² Peptides in an in Vitro Model of the Blood-Brain Barrier Cells. Journal of Biological Chemistry, 2008, 283, 34554-34562.	1.6	99
16	The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate AÎ² Fibril Formation without Increasing Protofibril Formation. Journal of Biological Chemistry, 2007, 282, 4916-4923.	1.6	96
17	Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. Journal of Experimental Medicine, 2022, 219, .	4.2	93
18	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 3176-3192.	1.7	92

#	Article	IF	Citations
19	Microfluidic Chemotaxis Platform for Differentiating the Roles of Soluble and Bound Amyloid-Î² on Microglial Accumulation. Scientific Reports, 2013, 3, 1823.	1.6	82
20	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 15.	4.4	74
21	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9645-E9654.	3.3	72
22	RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Human Molecular Genetics, 2013, 22, 4474-4484.	1.4	68
23	Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-Î² in Human Alzheimer Brain. PLoS ONE, 2011, 6, e14586.	1.1	66
24	Characterization of Oligomer Formation of Amyloid-Î² Peptide Using a Split-luciferase Complementation Assay. Journal of Biological Chemistry, 2011, 286, 27081-27091.	1.6	65
25	Brain interstitial oligomeric amyloid Î² increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB Journal, 2013, 27, 3239-3248.	0.2	57
26	Distinct Dendritic Spine and Nuclear Phases of Calcineurin Activation after Exposure to Amyloid-Î² Revealed by a Novel Fluorescence Resonance Energy Transfer Assay. Journal of Neuroscience, 2012, 32, 5298-5309.	1.7	54
27	CLAC Binds to Amyloid Î² Peptides through the Positively Charged Amino Acid Cluster within the Collagenous Domain 1 and Inhibits Formation of Amyloid Fibrils. Journal of Biological Chemistry, 2005, 280, 8596-8605.	1.6	52
28	ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-Î² peptide (1â€“40) at the bloodâ€“brain barrier. Neurochemistry International, 2008, 52, 956-961.	1.9	50
29	Substrate docking to Î³-secretase allows access of Î³-secretase modulators to an allosteric site. Nature Communications, 2010, 1, 130.	5.8	47
30	Patterns and severity of vascular amyloid in Alzheimerâ€™s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 569-587.	3.9	47
31	Amyloidâ€Î² peptide(1â€40) elimination from cerebrospinal fluid involves lowâ€density lipoprotein receptorâ€related protein 1 at the bloodâ€cerebrospinal fluid barrier. Journal of Neurochemistry, 2011, 118, 407-415.	2.1	46
32	Role of Apolipoprotein E in Î²-Amyloidogenesis. Journal of Biological Chemistry, 2015, 290, 15163-15174.	1.6	46
33	Analytical Method for Î²-Amyloid Fibrils Using CE-Laser Induced Fluorescence and Its Application to Screening for Inhibitors of Î²-Amyloid Protein Aggregation. Analytical Chemistry, 2007, 79, 4887-4891.	3.2	41
34	CLAC-P/Collagen Type XXV Is Required for the Intramuscular Innervation of Motoneurons during Neuromuscular Development. Journal of Neuroscience, 2014, 34, 1370-1379.	1.7	41
35	RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques. PLoS ONE, 2014, 9, e89901.	1.1	37
36	Neuronal activity and secreted amyloid Î² lead to altered amyloid Î² precursor protein and presenilin 1 interactions. Neurobiology of Disease, 2013, 50, 127-134.	2.1	32

#	Article	IF	Citations
37	Mostly Separate Distributions of CLAC- versus AÎ²40- or Thioflavin S-Reactivities in Senile Plaques Reveal Two Distinct Subpopulations of Î²-Amyloid Deposits. American Journal of Pathology, 2004, 165, 273-281.	1.9	30
38	Chronic cerebral hypoperfusion shifts the equilibrium of amyloid Î² oligomers to aggregation-prone species with higher molecular weight. Scientific Reports, 2019, 9, 2827.	1.6	27
39	Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model. Acta Neuropathologica Communications, 2020, 8, 67.	2.4	27
40	Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy. RNA Biology, 2021, 18, 1546-1554.	1.5	27
41	Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2015, 10, 20.	4.4	25
42	Identification of Small Molecule Inhibitors of Neurite Loss Induced by AÎ² peptide using High Content Screening. Journal of Biological Chemistry, 2012, 287, 8714-8723.	1.6	20
43	Self-assembly of FUS through its low-complexity domain contributes to neurodegeneration. Human Molecular Genetics, 2018, 27, 1353-1365.	1.4	19
44	ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. Neurobiology of Disease, 2022, 162, 105585.	2.1	19
45	Molecular Identification of AMY, an Alzheimer Disease Amyloid-Associated Protein. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1108-1117.	0.9	18
46	Immunoreactivity of Phage Library-derived Human Single-Chain Antibodies to Amyloid Beta Conformers In Vitro. Journal of Biochemistry, 2007, 143, 475-486.	0.9	17
47	Familial Amyotrophic Lateral Sclerosis-linked Mutations in Profilin 1 Exacerbate TDP-43-induced Degeneration in the Retina of Drosophila melanogaster through an Increase in the Cytoplasmic Localization of TDP-43. Journal of Biological Chemistry, 2016, 291, 23464-23476.	1.6	17
48	Roles of Collagen XXV and Its Putative Receptors PTPÏƒ/Î´ in Intramuscular Motor Innervation and Congenital Cranial Dysinnervation Disorder. Cell Reports, 2019, 29, 4362-4376.e6.	2.9	16
49	Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-Î² plaques. Acta Neuropathologica Communications, 2020, 8, 212.	2.4	13
50	Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid Î² fibrils. PLoS ONE, 2019, 14, e0219465.	1.1	11
51	Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimerâ€™s disease. IScience, 2022, 25, 103869.	1.9	7
52	Calcium-responsive transactivator (CREST) toxicity is rescued by loss of PBP1/ATXN2 function in a novel yeast proteinopathy model and in transgenic flies. PLoS Genetics, 2019, 15, e1008308.	1.5	5
53	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PSâ€1 mutations that lead to exceptionally high amyloidâ€Î² concentrations. Annals of Neurology, 2000, 48, 806-808.	2.8	3
54	Casein kinase 1Î´/Îµ phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration. Journal of Biological Chemistry, 2022, 298, 102191.	1.6	1

#	Article	IF	Citations
55	O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease. , 2011, 7, S103-S104.		0